SCHEMBL4128438

SCHEMBL4128438

O=Cc1ccc(CCCCOC2CCCCO2)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4C Q9H3R0 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MGLL Q99685 1/20 0.38
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CHEK1 O14757 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
P2RX3 P56373 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26908739 0.97 MEN1 (0.48) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL6202374 0.92 KDM4C (0.46) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL30865753 0.88 MEN1 (0.45) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL29963406 0.85 MEN1 (0.65) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL4021594 0.84 MEN1 (0.67) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL4118048 0.84 MEN1 (0.64) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL31073145 0.83 ICAM1 (0.42) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL18046352 0.83 KDM4C (0.46) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL10680254 0.82 MEN1 (0.51) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL4125006 0.82 MEN1 (0.51) MEN1KMT2AKDM4CL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209011-A1 HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER FLORATEK PHARMA S A (CH) 2024-06-27 US disclosed
US-20240209011-A1 HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER FLORATEK PHARMA S A (CH) 2024-06-27 US disclosed
US-20240132461-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER FLORATEK PHARMA S A (CH) 2024-04-25 US disclosed
EP-4288421-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER Floratek Pharma SA (CH) 2023-12-13 EP disclosed
EP-4284517-A1 HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER Floratek Pharma SA (CH) 2023-12-06 EP disclosed
US-20220411448-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS Floratek Pharma SA (CH) 2022-12-29 US disclosed
US-20220411448-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS Floratek Pharma SA (CH) 2022-12-29 US disclosed
WO-2022200540-A9 HETERO BENZYL AMINES AND THEIR USE TREATING CENTRAL NERVOUS SYSTEM DISORDERS Floratek Pharma SA (CH) 2022-11-17 WO disclosed
WO-2022200540-A1 HETERO BENZYL AMINES AND THEIR USE TREATING CENTRAL NERVOUS SYSTEM DISORDERS Floratek Pharma SA (CH) 2022-09-29 WO disclosed
WO-2022200542-A1 FLAVONOID POLYAMINES AND THEIR USE TREATING CENTRAL NERVOUS SYSTEM DISORDERS Floratek Pharma SA (CH) 2022-09-29 WO disclosed
WO-2022167696-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER Floratek Pharma SA (CH) 2022-08-11 WO disclosed
WO-2022162029-A1 HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER FLORATEK PHARMA AG (CH) 2022-08-04 WO disclosed
EP-4031538-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS Floratek Pharma AG (CH) 2022-07-27 EP disclosed
WO-2021053205-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS FLORATEK PHARMA AG (CH) 2021-03-25 WO disclosed
WO-2021053205-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS FLORATEK PHARMA AG (CH) 2021-03-25 WO disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240209011-A1 HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER PIK3CA, TP53, CDK4 MEN1 1580/4885KMT2A 1682/4885KDM4C 797/4885
US-20220411448-A1 CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS BDNF, NTRK2, NGF MEN1 3035/4885KMT2A 4496/4885KDM4C 4431/4885
US-20240132461-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER SRM, TP53, KDM5A MEN1 1103/4885KMT2A 155/4885KDM4C 15/4885
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AGTR1, AGTR2, AHR MEN1 2129/4885KMT2A 1253/4885KDM4C 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.